ArticleFrontiers in genetics2025
Identification of key ferroptosis-related genes and therapeutic target in nasopharyngeal carcinoma.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Ferroptosis in Nasopharyngeal Carcinoma: Mechanisms, Resistance, and Precision Therapeutic Opportunities.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Nasopharyngeal carcinoma (NPC) is a malignant tumor, but the role of ferroptosis-related genes in NPC remains unclear. This study aimed to identify ferroptosis-related therapeutic targets and explore their mechanisms in NPC. Method: NPC datasets and ferroptosis-related genes were obtained from GEO and FerrDB, respectively. Ferroptosis-related differentially expressed genes (DEGs) were identified, and Weighted Gene Co-expression Network Analysis (WGCNA) was used to pinpoint disease-related genes. Four machine learning algorithms screened hub genes, validated by ROC curves. Functional enrichment (GSEA, GSVA), drug prediction (DGIdb), immune infiltration analysis (CIBERSORT), and single-cell RNA sequencing (scRNA-seq) were performed. Result: From 3405 DEGs, 90 ferroptosis-related genes were identified, enriched in ferroptosis, IL-17, and p53 signaling pathways. WGCNA revealed 34 disease-related genes, and four hub genes (TBK1, KIF20A, SLC16A1, QSOX1) were selected, showing high diagnostic efficacy. GSEA/GSVA highlighted pathway differences between high/low expression groups. Eleven potential drugs were predicted, and immune analysis indicated increased macrophage M1 and neutrophil infiltration. scRNA-seq validated hub gene expression profiles. Conclusion: This study identified four ferroptosis hub genes in NPC, offering insights into its molecular mechanisms and potential diagnostic/therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.